tradingkey.logo

Mabwell Doses First Patient In Study For Triple-Negative Breast Cancer Post-ADC Treatment

ReutersAug 12, 2025 3:54 PM

- Mabwell Shanghai Bioscience Co Ltd 688062.SS:

  • MABWELL ANNOUNCES FIRST PATIENT DOSED IN THE US CLINICAL STUDY OF BULUMTATUG FUVEDOTIN IN TNBC PATIENTS PREVIOUSLY TREATED WITH ADCS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI